Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix Revenue for the 1st quarter of 2013

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2013.

Nanobiotix Revenue for the 1st quarter of 2013

Paris, France | Posted on May 15th, 2013

Activity

The revenue recorded by NANOBIOTIX during the first quarter of 2013 corresponds to the upfront payment (pro-rata share for such quarter) received by the Company from Taiwan-based PharmaEngine, within the framework of the licensing contract. NANOBIOTIX signed the licensing contract with PharmaEngine in August 2012, for the development and marketing of its lead product, NBTXR3 in the Asia-Pacific region. The upfront payment totaled €810,640 and is apportioned using the straight-line method between the date the contract was signed and the scheduled marketing launch in the region i.e. approximately 5 years. The amount is in line with the Company's strategy, focused on the development and marketing of NBTXR3.

NANOBIOTIX is focusing its efforts to progress clinical development of NBTXR3. The product is undergoing phase I trials in patients with advanced Soft Tissue Sarcoma (STS) at the Institut Gustave Roussy, France. NANOBIOTIX published positive interim results regarding the safety of NBTXR3 in the first group of patients in November 2012. This is an encouraging milestone in the clinical validation process of NBTXR3.

NANOBIOTIX plans to progress clinical trials of NBTXR3, and will initiate a study in head and neck cancer patients later in 2013.

The timing and progress of the clinical development of NBTXR3 are in line with the Company's expectations and original plan at IPO.

Nanobiotix will present the therapeutic approach NanoXray and NBTXR3 clinical data to a group of oncologists and radiation oncologists. The scientific meeting will be held on June 1st 2013 in Chicago, USA.

Next financial press release: revenue for the 2nd quarter of 2013, on 12 July 2013

####

About Nanobiotix
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
NANOBIOTIX
Laurent Levy
CEO and Co-founder
Tel: +33 (0)1 40 26 07 55


College Hill
Press Relations (Europe except France)
Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar
+44 (0)207 457 2020


NewCap.
Financial communication and Investor relations
Louis-Victor Delouvrier / Emmanuel Huynh
Tel: +33 (0)1 44 71 98 53


Yucatan
Press Relations
Annie-Florence Loyer / Nadège Le Lezec
Tel: +33 (0)1 53 63 27 27

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

WSU researchers 'watch' crystal structure change in real time: Breakthrough made possible by new Argonne facility July 27th, 2016

Enhancing molecular imaging with light: New technology platform increases spectroscopic resolution by 4 fold July 27th, 2016

New nontoxic process promises larger ultrathin sheets of 2-D nanomaterials July 27th, 2016

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

Nanomedicine

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016

Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016

New superconducting coil improves MRI performance: UH-led research offers higher resolution, shorter scan time July 23rd, 2016

Announcements

WSU researchers 'watch' crystal structure change in real time: Breakthrough made possible by new Argonne facility July 27th, 2016

Enhancing molecular imaging with light: New technology platform increases spectroscopic resolution by 4 fold July 27th, 2016

New nontoxic process promises larger ultrathin sheets of 2-D nanomaterials July 27th, 2016

Ultrasensitive sensor using N-doped graphene July 26th, 2016

Financial Reports

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

Nanobiotix revenue for Q2 2016 July 14th, 2016

Nanometrics to Announce Second Quarter Financial Results on July 26, 2016 July 6th, 2016

Nanometrics to Announce First Quarter Financial Results on April 26, 2016 April 5th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic